<DOC>
	<DOCNO>NCT00514488</DOCNO>
	<brief_summary>This phase III multicenter , open-label study design investigate efficacy ( hematological response , cytogenetic response molecular response ) feasibility ( tolerance , compliance safety ) tyrosine kinase inhibitor imatinib mesylate ( formerly STI 571 , GLIVEC , Novartis Pharma ) conventional dose ( 400 mg/daily ) compare high dose ( 800 mg/daily ) ( serial number protocol ICSG/CML/022 ) patient Ph+ chronic myeloid leukemia ( CML ) chronic phase ( CP ) previously untreated , high Sokal risk .</brief_summary>
	<brief_title>Imatinib Standard Dose ( 400 mg/Day ) Versus Imatinib High Dose ( 800 mg/Day )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Age &gt; /=18 year 2 . First chronic phase , less 6 month duration 3 . High Sokal 's risk 4 . Ph positive 5 . No previous treatment hydroxiurea . 6 . Performance status ( ECOG/WHO ) &lt; 2 7 . Written inform consent 1 . Age &lt; 18 2 . Low intermediate Sokal risk score . 3 . More 6 month diagnosis . 4 . Second chronic , accelerate blastic phase 5 . Scheduled allogeneic stem cell transplantation within 1 year diagnosis . 6 . Performance status ( ECOG/WHO ) &gt; 2 7 . Inability provide write informed consent 8 . Pregnancy 9 . Formal refusal recommendation safe contraception 10 . Alcohol drug addiction 11 . Altered hepatic renal function define AST/ALT bilirubine &gt; 3 time upper normal limit ( UNL ) creatinine &gt; 20mg/L 12 . Any disease condition advise responsible physician would make treatment dangerous patient would make patient ineligible study , include physical , psychiatric , social behavioural problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>STI 571</keyword>
	<keyword>CML022</keyword>
</DOC>